- Home
- CGO vs OVID Comparison
CGO vs OVID Comparison
Compare CGO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- OVID
- Stock Information
- Founded
- CGO 2004
- OVID 2014
- Country
- CGO United States
- OVID United States
- Employees
- CGO N/A
- OVID N/A
- Industry
- CGO Investment Managers
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- OVID Health Care
- Exchange
- CGO Nasdaq
- OVID Nasdaq
- Market Cap
- CGO 121.2M
- OVID 117.3M
- IPO Year
- CGO N/A
- OVID 2017
- Fundamental
- Price
- CGO $11.96
- OVID $1.39
- Analyst Decision
- CGO
- OVID Strong Buy
- Analyst Count
- CGO 0
- OVID 4
- Target Price
- CGO N/A
- OVID $3.13
- AVG Volume (30 Days)
- CGO 34.7K
- OVID 2.3M
- Earning Date
- CGO 01-01-0001
- OVID 11-13-2025
- Dividend Yield
- CGO 9.25%
- OVID N/A
- EPS Growth
- CGO N/A
- OVID N/A
- EPS
- CGO N/A
- OVID N/A
- Revenue
- CGO N/A
- OVID $6,651,000.00
- Revenue This Year
- CGO N/A
- OVID $1,086.57
- Revenue Next Year
- CGO N/A
- OVID N/A
- P/E Ratio
- CGO N/A
- OVID N/A
- Revenue Growth
- CGO N/A
- OVID 1070.95
- 52 Week Low
- CGO $7.90
- OVID $0.24
- 52 Week High
- CGO $10.93
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- CGO 49.22
- OVID 44.80
- Support Level
- CGO $11.89
- OVID $1.50
- Resistance Level
- CGO $12.14
- OVID $1.73
- Average True Range (ATR)
- CGO 0.16
- OVID 0.13
- MACD
- CGO -0.00
- OVID -0.05
- Stochastic Oscillator
- CGO 53.05
- OVID 11.24
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.